Glyoxal bis(guanylhydrazone) as an inhibitor of polyamine biosynthesis in tumour cells.
Glyoxal bis(guanylhydrazone), the parent compound of methylglyoxal bis(guanylhydrazone), was synthesized and tested for its ability to inhibit the biosynthesis of polyamines. It was found to be a powerful competitive inhibitor of adenosylmethionine decarboxylase (EC 4.1.1.50), yet the lack of the methyl group at the glyoxal portion increased the apparent Ki value for the enzyme by about 30-fold in comparison with methylglyoxal bis(guanylhydrazone). Glyoxal bis(guanylhydrazone) inhibited diamine oxidase (EC 1.4.3.6) activity as effectively as did methylglyoxal bis(guanylhydrazone). The cellular accumulation curves of glyoxal bis(guanylhydrazone) in L1210 cells were practically superimposable with those of methylglyoxal bis(guanylhydrazone), and the uptake of both compounds was distinctly stimulated by a prior treatment with 2-difluoromethylornithine. The drug decreased the concentration of spermidine in a dose-dependent manner and, in contrast with methylglyoxal bis(guanylhydrazone), without a concomitant accumulation of putrescine. The fact that putrescine concentrations were decreased in cells exposed to glyoxal bis(guanylhydrazone) was, at least in part, attributable to an inhibition of ornithine decarboxylase (EC 4.1.1.17) activity in cells treated with the compound. Under these experimental conditions equivalent concentrations of methylglyoxal bis(guanylhydrazone) [1,1'-[(methylethanediylidine)dinitrilo]diguanidine] elicited large increases in the enzyme activity. When combined with difluoromethylornithine, glyoxal bis(guanylhydrazone) potentiated the growth-inhibitory effect of that drug. Taking into consideration the proven anti-leukaemic activity of glyoxal bis(guanylhydrazone), its effectiveness to inhibit spermidine biosynthesis (without raising the concentration of putrescine) as well as its suitability for combined use with inhibitors of ornithine decarboxylase, this drug is apparently worthy of further testing in tumour-bearing animals, especially in combination with difluoromethylornithine or related inhibitors of ornithine decarboxylase.
D012437:Adenosylmethionine Decarboxylase / Q000037:antagonists & inhibitors; D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000201:enzymology; D002478:Cells, Cultured; D004273:DNA, Neoplasm / Q000378:metabolism; D000518:Eflornithine; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D007939:Leukemia L1210 / Q000378:metabolism; D051379:Mice; D008935:Mitoguazone / Q000031:analogs & derivatives / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009952:Ornithine / Q000031:analogs & derivatives / Q000494:pharmacology; D011073:Polyamines / Q000378:metabolism*
D004273:DNA, Neoplasm; D006146:Guanidines; D009363:Neoplasm Proteins; D011073:Polyamines; C042426:glyoxal bis(guanylhydrazone); D009952:Ornithine; D006631:Amine Oxidase (Copper-Containing); D012437:Adenosylmethionine Decarboxylase; D008935:Mitoguazone; D000518:Eflornithine